Global Erectile Dysfunction Drugs Market Size to Forecasted to Surge $7.1 Billion Growth by 2032, Exhibit a CAGR of 9%

[220 + Pages Research Study] According to a market research study published by The Brainy Insights, the demand analysis of global erectile dysfunction drugs market size & share revenue was valued at around USD 3.0 billion in 2022 and is estimated to grow about USD 7.1 billion by 2032, at a CAGR of approximately 5.72% between 2023 and 2032. The global demand for erectile dysfunction drugs is increasing due to an ageing population and a high prevalence of chronic conditions such as kidney failure, hormonal imbalance, diabetes, hypertension, and neurological problems.

Newark, Sept. 18, 2023 (GLOBE NEWSWIRE) — The Brainy Insights estimates that the USD 3.0 billion erectile dysfunction drugs market will reach USD 7.1 billion by 2032. Erectile dysfunction (ED) has become more widespread, even among young people, and is a rising health issue that significantly influences men’s quality of life. Globally, ED cases are predicted to reach about 322 million by the end of 2025. According to overwhelming evidence, erectile dysfunction drugs (EDMs) are increasingly being utilised as a sexual enhancement aid among men who do not have a medical rationale. Recreational EDM use has been associated with higher sexual risk behaviours, an increased risk of STIs, including HIV infection, and a high rate of concurrent illegal substance use.

Request to Download Sample Research Report –

Report Coverage Details

Report Coverage Details
Forecast Period 2023-2032
Base Year 2022
Market Size in 2022 USD 3.0 Billion
Market Size in 2032 USD 7.1 Billion
No. of Pages in Report 232
Segments Covered Product
Drivers Rising Popularity of Nicotine
Opportunities Generic Manufacturers
Restraints Patent Expiration

North America to account for the largest market size during the forecast period.

North America is expected to have the essential erectile dysfunction drugs market share. Because of established healthcare infrastructure, rising demand for erectile dysfunction drugs, and research and development programmes aimed at producing novel therapeutic compounds, the North American region owns a considerable number of market shares.

The viagra segment dominated the market with the most significant revenue of USD 1.11 billion.

The viagra segment dominated the market with the most significant revenue of USD 1.11 billion. Viagra is the most commonly prescribed first-line medication for erectile dysfunction. Viagra is also used to treat the underlying cause of ED, pulmonary arterial hypertension. According to an article published in June 2021 by Hims & Hers Health, Inc., more than 95% of erectile dysfunctional males who used sildenafil were satisfied with how it changed their erections.

Procure Complete Research Report –

Market Dynamics:

Drivers: Increasing Adoption

Adopting a sedentary lifestyle and related stress, the expanding geriatric population, and the comorbidity of erectile dysfunction with heart disease and diabetes are all factors driving the erectile dysfunction (ED) drugs market. Sedentism, drunkenness, and smoking significantly raise the chance of erectile dysfunction. Alcohol use, poor glycemic control, age, and diabetes duration were all predictors of erectile dysfunction in a study published in BMC Endocrine Disorders in July 2021. In 2021, 72.2% of persons worldwide were discovered to have erectile dysfunction. Thus, ageing, diabetes, alcohol consumption, and poor glycemic control were discovered to impact erectile dysfunction, fueling market expansion.

Restraint: Side Effects

Common reasons for erectile dysfunction include drug side effects, neurogenic illnesses, ageing, multiple sclerosis, psychological factors, diabetes, and lifestyle changes.

Opportunity: Rising Hypertension

The most frequent risk factor in men is erectile dysfunction, which worsens with age. Ageing and older men usually have comorbidities such as diabetes, chronic obstructive pulmonary disease, hypertension, cardiovascular disease, and many others; they also see a physician for sexual function deficits, most commonly erectile dysfunction (ED). According to the NIH paper released in June 2021, sexual dysfunctions are widespread in patients with diabetes and can be caused by several vascular, neurologic, and hormonal derangements. Furthermore, ED cases are frequently associated with increased obesity, diabetes, and cardiovascular problems. Another essential condition connected to male erectile dysfunction is hypertension.

Challenge: Patient Unwillingness

Patients’ unwillingness to seek therapy and poor adherence to ED drugs limit market expansion.

Interested to Procure the Research Report? Inquire Before Buying –

Some of the major players operating in the erectile dysfunction drugs market are:

● Pfizer Inc.
● Eli Lilly and Company
● Teva Pharmaceutical Industries Ltd
● Sanofi
● Sun Pharmaceutical Industries Ltd
● Bayer AG
● Petros Pharmaceuticals, Inc.
● VIVUS, Inc.
● Auxilium Pharmaceuticals, Inc.
● Adamed

Key Segments cover in the market:

By Product:

● Viagra
● Cialis
● Levitra/Staxyn
● Stendra/Spedra
● Zydena
● Vitaros
● Others

Have Any Query? Ask Our Experts:

About the report:

The global erectile dysfunction drugs market is analyzed based on value (USD billion). All the segments have been analyzed on a worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes Porter’s five forces model, attractiveness analysis, raw material analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients’ objectives of high-quality output within a short span of time. We provide both customized (clients’ specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients’ requirements whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D
Head of Business Development
Phone: +1-315-215-1633

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More